XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. Acta Med Philipp [Internet]. 2015 Jun. 30 [cited 2025 Apr. 5];49(2). Available from: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/988